Cimeio Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Website
www.cimeio.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cimeio Therapeutics
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.Explore more
Cimeio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cimeio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cimeio Therapeutics
Website visits: Recent activity has been detected on your website
Click to see if Cimeio Therapeutics had a recent Job posting/layoffs
Cimeio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cimeio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cimeio Therapeutics has new funding data
Earning: See what the market has to say on Cimeio Therapeutics recently announced quarterly report
Product Launch: Get notified when Cimeio Therapeutics launches new products
Check out if Cimeio Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Cimeio Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Cimeio Therapeutics
Compare insights from companies similar to Cimeio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cimeio Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cimeio Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cimeio Therapeutics.
Cimeio Therapeutics financials insights
Gather financial insights about Cimeio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$50M
Cimeio Therapeutics Tech Stack
A closer look at the technologies used by Cimeio Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Event
Events
Funding
Funding
Cimeio Therapeutics News & Media
Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and protected from the ADC via shielded hematopoietic stem cells (HSCs). The findings point to a novel and potentially universal approach to treating blood cancers. CD45 is highly expressed on blood cancers but also on healthy blood cells. ThisCimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT
BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore. The abstract is titled “Molecular Shielding of CD52 Retains Expression, Anti-Phagocytic Don’t Eat Me Function and Protects from Alemtuzumab-Mediated Depletion.” The study is the first showing that T cells expresCimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH
BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting in San Diego. The two studies provide further evidence that epitope editing allows for the development of powerful immunotherapies that would not be safe to administer without first protecting healthy cells. The first abstract, titled “HemaCimeio Therapeutics Announces Poster Presentations at ASH 2023
BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two abstracts to be presented at the American Society of Hematology meeting in December 2023 in San Diego. The first abstract is titled “Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases.” These data demonstrate that CD45 antibody-drug conjugat
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cimeio Therapeutics
Sign Up For FreeTo access detailed company insights
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.... Read More
